Personal information

Websites & social links

Google Scholar

Other IDs

ResearcherID: M-7032-2016
Scopus Author ID: 6504391249
Loop profile: 1573499

Countries

Australia

Activities

Collapse all

Employment (8)

Qatar Biomedical Research Institute: Doha, Ad Dawhah, QA

2020-01-01 to present | Senior Scientist (Cancer Research Center)
Employment
Source: Self-asserted source
Fares Al-Ejeh

QIMR Berghofer Medical Research Institute: Herston, QLD, AU

2015-03-01 to present | Senior Research Fellow (Cancer Division)
Employment
Source: Self-asserted source
Fares Al-Ejeh

QIMR Berghofer Medical Research Institute: Herston, QLD , AU

2014-01-01 to present | ARC Future Fellow (Cancer Division)
Employment
Source: Self-asserted source
Fares Al-Ejeh

QIMR Berghofer Medical Research Institute: Herston, QLD, AU

2015-08-05 to 2019-12-31 | Team Head - Personalised Medicine Team (Cancer Division)
Employment
Source: Self-asserted source
Fares Al-Ejeh

QIMR Berghofer Medical Research Institute: Herston, QLD , AU

2012-01-01 to 2014-12-31 | Senior Research Officer (Cancer Division)
Employment
Source: Self-asserted source
Fares Al-Ejeh

QIMR Berghofer Medical Research Institute: Herston, QLD, AU

2010-01-11 to 2011-12-31 | Postdoctoral Scientist (Cancer Division)
Employment
Source: Self-asserted source
Fares Al-Ejeh

Oncaidia Ltd.: Adelaide, SA, AU

2008-01-01 to 2009-12-31 | Chief Scientific Advisor
Employment
Source: Self-asserted source
Fares Al-Ejeh

Oncaidia Ltd. funded postdoctoral scientist - Royal Adelaide Hospital: Adelaide, SA, AU

2004-11-01 to 2009-12-31 | Oncaidia Ltd. funded postdoctoral scientist (Hanson Institute)
Employment
Source: Self-asserted source
Fares Al-Ejeh

Education and qualifications (2)

University of Wollongong: Wollongong, NSW, AU

2001-02-28 to 2005-07-15 | Ph.D. Biological Sciences (Biological Sciences)
Education
Source: Self-asserted source
Fares Al-Ejeh

University of Wollongong: Wollongong, NSW, AU

1997-03-05 to 2001-07-14 | Bachelor (Hons) Biotechnology (Biological Sciences)
Education
Source: Self-asserted source
Fares Al-Ejeh

Funding (3)

The MEK5-ERK5 pathway in triple negative breast cancer: progression and therapy

2016-01 to 2017-12 | Grant
Cancer Council Queensland (QLD, QLD, AU)
Source: Self-asserted source
Fares Al-Ejeh

From transcriptome profiling to targeted therapies in triple negative breast cancer

2015-01 to present | Grant
National Health and Medical Research Council (ACT, ACT, AU)
Source: Self-asserted source
Fares Al-Ejeh

Combination of EGFR-directed radioimmunotherapy with chemotherapy and DNA repair inhibitors for pancreatic and triple negative breast cancer

2014-01 to present | Award
Australian Research Council (Canberra, AU)
Source: Self-asserted source
Fares Al-Ejeh

Works (50 of 105)

Items per page:
Page 1 of 3

Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

Cancer Epidemiology, Biomarkers & Prevention
2023-12-01 | Journal article
DOI: 10.1158/1055-9965.EPI-23-0520
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Data from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.c.6960604
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Data from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.c.6960604.v1
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Figure S1 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710584.v1
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Figure S1 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710584
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Figure S2 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710581
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Figure S2 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710581.v1
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Figure S3 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710578
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Figure S3 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710578.v1
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Figure S4 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710575
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Figure S4 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710575.v1
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Figure S5 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710572
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Figure S5 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710572.v1
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Table S1 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710569.v1
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Table S1 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710569
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Table S2 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710566
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Table S2 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis

2023-12-01 | Preprint
DOI: 10.1158/1055-9965.24710566.v1
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

Data from G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6531297
Contributors: Gregory M. Kelly; Fares Al-Ejeh; Robert McCuaig; Francesco Casciello; Nabilah Ahmad Kamal; Blake Ferguson; Antonia L. Pritchard; Sayed Ali; Ines P. Silva; James S. Wilmott et al.
Source: check_circle
Crossref

Data from G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6531297.v1
Contributors: Gregory M. Kelly; Fares Al-Ejeh; Robert McCuaig; Francesco Casciello; Nabilah Ahmad Kamal; Blake Ferguson; Antonia L. Pritchard; Sayed Ali; Ines P. Silva; James S. Wilmott et al.
Source: check_circle
Crossref

Supplementary Figures from G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22484013.v1
Contributors: Gregory M. Kelly; Fares Al-Ejeh; Robert McCuaig; Francesco Casciello; Nabilah Ahmad Kamal; Blake Ferguson; Antonia L. Pritchard; Sayed Ali; Ines P. Silva; James S. Wilmott et al.
Source: check_circle
Crossref

Supplementary Figures from G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22484013
Contributors: Gregory M. Kelly; Fares Al-Ejeh; Robert McCuaig; Francesco Casciello; Nabilah Ahmad Kamal; Blake Ferguson; Antonia L. Pritchard; Sayed Ali; Ines P. Silva; James S. Wilmott et al.
Source: check_circle
Crossref

Supplementary Tables from G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22484010.v1
Contributors: Gregory M. Kelly; Fares Al-Ejeh; Robert McCuaig; Francesco Casciello; Nabilah Ahmad Kamal; Blake Ferguson; Antonia L. Pritchard; Sayed Ali; Ines P. Silva; James S. Wilmott et al.
Source: check_circle
Crossref

Supplementary Tables from G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22484010
Contributors: Gregory M. Kelly; Fares Al-Ejeh; Robert McCuaig; Francesco Casciello; Nabilah Ahmad Kamal; Blake Ferguson; Antonia L. Pritchard; Sayed Ali; Ines P. Silva; James S. Wilmott et al.
Source: check_circle
Crossref

Cancer incidence and mortality estimates in Arab countries in 2018: A GLOBOCAN data analysis

2022-10-18 | Preprint
DOI: 10.1101/2022.10.12.22280986
Contributors: Mariam Al-Muftah; Fares Al-Ejeh
Source: check_circle
Crossref

A short ERK5 isoform modulates nucleocytoplasmic shuttling of active ERK5 and associates with poor survival in breast cancer

bioRxiv
2021 | Journal article
DOI: 10.1101/2021.03.23.436061
Source: Self-asserted source
Fares Al-Ejeh

Epigenome erosion drives neural crest-like phenotypic mimicry in triple-negative breast cancer and other SOX10+ malignancies

bioRxiv
2021 | Journal article
DOI: 10.1101/2021.03.30.437624
Source: Self-asserted source
Fares Al-Ejeh

G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

Clinical Cancer Research
2021-05-01 | Journal article
DOI: 10.1158/1078-0432.CCR-20-3463
Contributors: Gregory M. Kelly; Fares Al-Ejeh; Robert McCuaig; Francesco Casciello; Nabilah Ahmad Kamal; Blake Ferguson; Antonia L. Pritchard; Sayed Ali; Ines P. Silva; James S. Wilmott et al.
Source: check_circle
Crossref

Robust prognostic signatures derived from proteomic panel profiling of plasma from patients with severe COVID-19 complications

2021-03 | Preprint
DOI: 10.21203/rs.3.rs-126482/v1
OTHER-ID:

PPR294026
Contributors: Al-Nesf M; Abdesselem H; Bensmail I; Ibrahim S; Saeed W; Mohammed S; Razok A; Alhussain H; Aly R; Maslamani MA et al.
Source: Self-asserted source
Fares Al-Ejeh via Europe PubMed Central

Differential gene expression of tumor-infiltrating CD8+ T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis

Journal for ImmunoTherapy of Cancer
2020-09 | Journal article
DOI: 10.1136/jitc-2020-001294
Contributors: Reem Saleh; Varun Sasidharan Nair; Salman M Toor; Rowaida Z Taha; Khaled Murshed; Mahmood Al-Dhaheri; Mahwish Khawar; Mahir Abdulla Petkar; Mohamed Abu Nada; Fares Al-Ejeh et al.
Source: check_circle
Crossref

G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome.

Theranostics
2020-03-15 | Journal article
DOI: 10.7150/thno.41453
PMID: 32292512
PMC: PMC7150496
Source: Self-asserted source
Fares Al-Ejeh

Clinicopathologic significance of nuclear HER4 and phospho-YAP(S127) in human breast cancers and matching brain metastases

Therapeutic Advances in Medical Oncology
2020-01 | Journal article
DOI: 10.1177/1758835920946259
Contributors: Priyakshi Kalita-de Croft; Malcolm Lim; Haarika Chittoory; Xavier M. de Luca; Jamie R. Kutasovic; Bryan W. Day; Fares Al-Ejeh; Peter T. Simpson; Amy E. McCart Reed; Sunil R. Lakhani et al.
Source: check_circle
Crossref

Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study

The journal of pathology. Clinical research
2019 | Journal article
DOI: 10.1002/cjp2.118
EID:

2-s2.0-85059492826
Contributors: Kutasovic, J.R.; McCart Reed, A.E.; Males, R.; Sim, S.; Saunus, J.M.; Dalley, A.; McEvoy, C.R.; Dedina, L.; Miller, G.; Peyton, S. et al.
Source: Self-asserted source
Fares Al-Ejeh via Scopus - Elsevier

Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer

JCI insight
2019 | Journal article
DOI: 10.1172/jci.insight.124092
EID:

2-s2.0-85062406963
Contributors: Wiegmans, A.P.; Saunus, J.M.; Ham, S.; Lobb, R.J.; Kutasovic, J.R.; Dalley, A.J.; Miranda, M.; Atkinson, C.; Foliaki, S.T.; Ferguson, K. et al.
Source: Self-asserted source
Fares Al-Ejeh via Scopus - Elsevier

Overexpression of miRNA-25-3p inhibits Notch1 signaling and TGF-β-induced collagen expression in hepatic stellate cells.

Scientific reports
2019-06-12 | Journal article
DOI: 10.1038/s41598-019-44865-1
PMID: 31189969
PMC: PMC6561916
Source: Self-asserted source
Fares Al-Ejeh

Proteomic Analysis of the Breast Cancer Brain Metastasis Microenvironment

International Journal of Molecular Sciences
2019-05-22 | Journal article
DOI: 10.3390/ijms20102524
Contributors: Priyakshi Kalita-de Croft; Jasmin Straube; Malcolm Lim; Fares Al-Ejeh; Sunil R. Lakhani; Jodi M. Saunus
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.

Nature communications
2019-04-15 | Journal article
DOI: 10.1038/s41467-018-08053-5
PMID: 30988301
PMC: PMC6465407
Source: Self-asserted source
Fares Al-Ejeh
grade
Preferred source (of 2)‎

A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer

Nature Genetics
2018 | Journal article
DOI: 10.1038/s41588-018-0132-x
EID:

2-s2.0-85048695897
Contributors: Wu, L.; Shi, W.; Long, J.; Guo, X.; Michailidou, K.; Beesley, J.; Bolla, M.K.; Shu, X.-O.; Lu, Y.; Cai, Q. et al.
Source: Self-asserted source
Fares Al-Ejeh via Scopus - Elsevier

EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma.

Cancers
2018-12-17 | Journal article
DOI: 10.3390/cancers10120519
PMID: 30562956
PMC: PMC6316644
Source: Self-asserted source
Fares Al-Ejeh
grade
Preferred source (of 3)‎

Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient

Breast Cancer Research and Treatment
2018-02 | Journal article
DOI: 10.1007/s10549-018-4719-9
Part of ISSN: 0167-6806
Contributors: Julie Johnson; Darrell C. Bessette; Jodi M. Saunus; Chanel E. Smart; Sarah Song; Rebecca L. Johnston; Sibylle Cocciardi; Esdy N. Rozali; Cameron N. Johnstone; Ana Christina Vargas et al.
Source: Self-asserted source
Fares Al-Ejeh via Crossref Metadata Search
grade
Preferred source (of 2)‎

EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.

Leukemia
2017 | Journal article
DOI: 10.1038/leu.2016.371
WOSUID:

MEDLINE:27922598
Contributors: Charmsaz, S; Al-Ejeh, F; Yeadon, T M; Miller, K J; Smith, F M; Stringer, B W; Moore, A S; Lee, F-T; Cooper, L T; Stylianou, C et al.
Source: Self-asserted source
Fares Al-Ejeh via ResearcherID
grade
Preferred source (of 2)‎

Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage

American Journal of Human Genetics
2017 | Journal article
DOI: 10.1016/j.ajhg.2017.07.007
WOSUID:

WOS:000406854800009
Contributors: Betts, Joshua A.; Marjaneh, Mahdi Moradi; Al-Ejeh, Fares; Lim, Yi Chieh; Shi, Wei; Sivakumaran, Haran; Tropee, Romain; Patch, Ann-Marie; Clark, Michael B.; Bartonicek, Nenad et al.
Source: Self-asserted source
Fares Al-Ejeh via ResearcherID
grade
Preferred source (of 2)‎

Ssb1 and Ssb2 cooperate to regulate mouse hematopoietic stem and progenitor cells by resolving replicative stress

Blood
2017 | Journal article
DOI: 10.1182/blood-2016-06-725093
WOSUID:

WOS:000400555800008
Contributors: Shi, Wei; Vu, Therese; Boucher, Didier; Biernacka, Anna; Nde, Jules; Pandita, Raj K.; Straube, Jasmin; Boyle, Glen M.; Al-Ejeh, Fares; Nag, Purba et al.
Source: Self-asserted source
Fares Al-Ejeh via ResearcherID
grade
Preferred source (of 2)‎

The development of personalized diagnostic tests and therapeutic strategies in breast cancer

Cancer Research
2017 | Journal article
DOI: 10.1158/1538-7445.SABCS16-P6-09-47
WOSUID:

WOS:000397999002300
Contributors: Kutasovic, J. R.; Rozali, E.; Miranda, M.; Lakhani, S. R.; Al-Ejeh, F.
Source: Self-asserted source
Fares Al-Ejeh via ResearcherID
grade
Preferred source (of 4)‎

THE DYSTROGLYCAN COMPLEX PROMOTES MESENCHYMAL-LIKE GLIOBLASTOMA THROUGH INTERACTION WITH EPHA RECEPTOR TYROSINE KINASES

Neuro-Oncology
2017 | Journal article
WOSUID:

WOS:000402732900085
Contributors: Day, B. W.; Al-Ejeh, F.; Bruce, Z. C.; Ensbey, K. S.; Robertson, T.; Stringer, B. W.; Rich, J. N.; Lathia, J. D.; Campbell, K. P.; Boyd, A. W.
Source: Self-asserted source
Fares Al-Ejeh via ResearcherID

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.

Nature genetics
2017-10-23 | Journal article
DOI: 10.1038/ng.3785
PMID: 29058716
PMC: PMC5808456
Source: Self-asserted source
Fares Al-Ejeh
grade
Preferred source (of 3)‎

Multidimensional phenotyping of breast cancer cell lines to guide preclinical research

Breast Cancer Research and Treatment
2017-09-09 | Journal article
DOI: 10.1007/s10549-017-4496-x
Contributors: Jodi M. Saunus; Chanel E. Smart; Jamie R. Kutasovic; Rebecca L. Johnston; Priyakshi Kalita-de Croft; Mariska Miranda; Esdy N. Rozali; Ana Cristina Vargas; Lynne E. Reid; Eva Lorsy et al.
Source: Self-asserted source
Fares Al-Ejeh via Crossref Metadata Search
grade
Preferred source (of 3)‎

MITF and BRN2 contribute to metastatic growth after dissemination of melanoma

Scientific Reports
2017-09-07 | Journal article
DOI: 10.1038/s41598-017-11366-y
Contributors: Jacinta L. Simmons; Carly J. Pierce; Fares Al-Ejeh; Glen M. Boyle
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis

Proceedings of the National Academy of Sciences
2017-06 | Journal article
DOI: 10.1073/pnas.1618706114
Contributors: Francesco Casciello; Fares Al-Ejeh; Greg Kelly; Donal J. Brennan; Shin Foong Ngiow; Arabella Young; Thomas Stoll; Karolina Windloch; Michelle M. Hill; Mark J. Smyth et al.
Source: Self-asserted source
Fares Al-Ejeh via Crossref Metadata Search
grade
Preferred source (of 3)‎

Quinazolinone derivatives as inhibitors of homologous recombinase RAD51

Bioorganic & Medicinal Chemistry Letters
2017-05 | Journal article
DOI: 10.1016/j.bmcl.2017.05.039
Contributors: Ambber Ward; Lilong Dong; Jonathan M. Harris; Kum Kum Khanna; Fares Al-Ejeh; David P. Fairlie; Adrian P. Wiegmans; Ligong Liu
Source: Self-asserted source
Fares Al-Ejeh via Crossref Metadata Search
grade
Preferred source (of 3)‎

P01.07 The Dystroglycan Complex Promotes Mesenchymal-Like Glioblastoma through Interaction with EphA Receptor Tyrosine Kinases

Neuro-Oncology
2017-04 | Journal article
DOI: 10.1093/neuonc/nox036.083
Contributors: B. W. Day; F. Al-Ejeh; Z. C. Bruce; K. S. Ensbey; T. Robertson; B. W. Stringer; J. N. Rich; J. D. Lathia; K. P. Campbell; A. W. Boyd
Source: Self-asserted source
Fares Al-Ejeh via Crossref Metadata Search
Items per page:
Page 1 of 3

Peer review (3 reviews for 3 publications/grants)

Review activity for F1000Research. (1)
Review activity for Nature neuroscience. (1)
Review activity for Oncogene. (1)
How many people are using ORCID?